Patents by Inventor Richard L. Momparler

Richard L. Momparler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selectable marker for genetically engineered cells and tissues
    Publication number: 20040115800
    Abstract: The present invention relates to selectable marker gene, method of producing genetically modified cells allowing expression of a bicistronic vector, and ex vivo gene therapy applications. The invention also relates to selection of genetically engineered cells from the mixed population, prior to implantation in vivo. The invention describes the human cytidine deaminase (CD) gene as an ex vivo dominant selectable marker in gene-modified primary cells with cytosine nucleoside analogues. A bicistronic retrovector comprising the human CD coding sequence and the enhanced green fluorescent protein (GFP) reporter gene is used for the transduction of cells. The invention describes the introduction of CD gene in cell and gene therapy applications for the ex vivo dominant selection of genetically engineered cells.
    Type: Application
    Filed: December 15, 2003
    Publication date: June 17, 2004
    Inventors: Richard L Momparler, Jacques Galipeau, Nicoletta Eliopoulus
  • Cytidine deaminase cDNA as a positive selectable marker for gene transfer, gene therapy and protein synthesis
    Patent number: 6083719
    Abstract: The present invention relates to a DNA sequence for the human cytidine deaminase that has been engineered into an eukaryotic expression vector, thereby permitting cytidine deaminase expression in mammalian cells. Cytidine deaminase expression confers resistance to cytosine nucleoside analogs, such as cytosine arabinoside, and can be used as a positive selectable marker. The expression of cytidine deaminase in cells protects them from the toxic effects of cytosine nucleoside analogs. Such a resistance provides applications for gene therapy of malignant, immune and viral diseases. A bacterial expression vector containing the gene can be used to produce cytidine deaminase in large quantities.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: July 4, 2000
    Assignee: Hopital Sainte-Justine
    Inventors: Richard L. Momparler, Josee Laliberte, Denis Cournoyer, Nicoletta Eliopoulos
  • Methods of treatment
    Patent number: 5547947
    Abstract: A method of inducing inhibition or loss of cell proliferation in solid tumors utilizing a Vitamin D.sub.3 analog, as well as a method of inducing loss of cell proliferation in solid tumors utilizing trans retinoic acid and a Vitamin D.sub.3 analog.In another aspect, a method of inducing inhibition or loss of cell proliferation in solid tumors utilizing a Vitamin D.sub.3 metabolite, as well as a method of inducing loss of cell proliferation in solid tumors utilizing trans retinoic acid and a Vitamin D.sub.3 metabolite.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: August 20, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Benoit T. Dore, Richard L. Momparler, Milan R. Uskokovic